全文获取类型
收费全文 | 6407篇 |
免费 | 332篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 144篇 |
妇产科学 | 129篇 |
基础医学 | 851篇 |
口腔科学 | 118篇 |
临床医学 | 586篇 |
内科学 | 1750篇 |
皮肤病学 | 192篇 |
神经病学 | 499篇 |
特种医学 | 118篇 |
外科学 | 629篇 |
综合类 | 19篇 |
预防医学 | 699篇 |
眼科学 | 60篇 |
药学 | 421篇 |
中国医学 | 20篇 |
肿瘤学 | 506篇 |
出版年
2023年 | 51篇 |
2022年 | 114篇 |
2021年 | 239篇 |
2020年 | 106篇 |
2019年 | 230篇 |
2018年 | 272篇 |
2017年 | 129篇 |
2016年 | 154篇 |
2015年 | 159篇 |
2014年 | 272篇 |
2013年 | 344篇 |
2012年 | 532篇 |
2011年 | 615篇 |
2010年 | 304篇 |
2009年 | 277篇 |
2008年 | 412篇 |
2007年 | 416篇 |
2006年 | 383篇 |
2005年 | 432篇 |
2004年 | 307篇 |
2003年 | 336篇 |
2002年 | 252篇 |
2001年 | 33篇 |
2000年 | 27篇 |
1999年 | 39篇 |
1998年 | 53篇 |
1997年 | 52篇 |
1996年 | 26篇 |
1995年 | 23篇 |
1994年 | 18篇 |
1993年 | 17篇 |
1992年 | 14篇 |
1991年 | 9篇 |
1990年 | 14篇 |
1989年 | 15篇 |
1988年 | 8篇 |
1987年 | 15篇 |
1986年 | 5篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1976年 | 4篇 |
1974年 | 6篇 |
1973年 | 4篇 |
1964年 | 3篇 |
1963年 | 3篇 |
排序方式: 共有6776条查询结果,搜索用时 15 毫秒
71.
R Salazar M Navarro F Losa V Alonso M Gallén F Rivera M Benavides P Escudero E González B Massutí A Gómez M Majem E Aranda 《Clinical & translational oncology》2012,14(8):592-598
Introduction
A prospective phase II study was conducted to assess the clinical activity and tolerability of oxaliplatin, capecitabine, and radiotherapy (RT) for neoadjuvant therapy of stages II?CIII rectal cancer.Materials and methods
Patients with histologically confirmed stages II?CIII (T3?CT4 and/or N+) resectable rectal adenocarcinoma were eligible. Capecitabine was administered at 825?mg/m2 twice daily for 5?days/week and oxaliplatin at 50?mg/m2 on day 1 weekly for 5?weeks starting the first day of RT (before RT). RT consisted of a total dose of 45?Gy delivered in 25 fractions of 1.8?Gy, 5?days per week, for 5?weeks.Results
A total of 46 patients were included (35 male, 10 female, median age 62?years). TNM Stage was T3 in 43 patients and T4 in 2. Twenty-eight patients had suspected nodal involvement. The intended chemoradiation treatment was completed in 94?% patients. Grade 3/4 toxicity included lymphocytopenia (6 patients), diarrhea (4 patients), emesis (2 patients), asthenia (3 patients), anorexia (1 patient), and hepatic toxicity (1 patient). Grade 1 neurotoxicity occurred in 18 patients, Grade 2 neurotoxicity in 3, and Grade 1 palmoplantar erythrodysesthesia in 2. Forty-two patients underwent surgery (complete resection 95?%, sphincter-saving operation 55?%). The overall pathologic response rate was 83?%, with a pathologic complete response (pCR) rate of 11.9?% (95?% CI 4.0?C25.6).Conclusions
The pCR rate observed with oxaliplatin plus capecitabine and RT did not reach the pre-specified criteria of efficacy in this trial, which is in line with recent results of randomized phase III trials. 相似文献72.
María Carmen Riesco Martínez Andrés J. Muñoz Martín Pamela Zamberk Majlis Jorge Adeva Alfonso Pilar Sabin Domínguez Pilar García Alfonso Ricardo Pérez Fernández 《Clinical & translational oncology》2009,11(8):552-553
An 80-year-old man was admitted to hospital with low-grade fever, weight loss, asthenia and anorexia. Physical examination
revealed generalised ichthyosis with palmoplantar hyperkeratosis. CT scan showed retroperitoneal and inguinal lymph node enlargement.
An inguinal lymph node biopsy revealed Hodgkin’s disease (nodular-sclerosing subtype). The patient received chemotherapy,
showing a clear improvement of both skin lesions and lymph nodes. 相似文献
73.
非小细胞肺癌(non-small cell lung cancer, NSCLC)约占肺癌总病例数的80%-85%,对于III期患者 来说,NSCLC约占肺癌总病例数的40%.不可切除III期NSCLC的治疗为以铂类为基础的化疗联合胸部放疗. 本文将综述正在研发中且有可能用于联合治疗的新型靶向制剂.其中最具前景的策略之一为表皮生长因子受 体(epidermal growth factor receptor, EGFR)通路的抑制.放疗可激活EGFR信号,通过诱导细胞增殖并增强DNA 修复而导致放疗抵抗.几项临床前模型研究表明西妥昔单抗与放疗联合具有协同效应.几项II期试验评估了西 妥昔单抗与放疗同步使用的安全性与疗效,结果喜人.吉非替尼对多种细胞系具有放疗增敏作用,其与放疗 的联合已被试验用于不可切除III期NSCLC的治疗.然而,放化疗后使用吉非替尼作为维持治疗的结果不容乐 观.一项I期试验评估了厄洛替尼与放化疗联合的疗效.放疗可通过损伤细胞膜、DNA以及微血管内皮细胞而 诱导肿瘤死亡,而这反过来可增加促血管生成生长因子的产生.抗血管生长制剂可降低血管密度,但可改善 肿瘤的含氧量.应用血管内皮生长因子受体(vascular endothelial growth factor receptor, VEGFR)抑制剂可通过阻 断亚致死量辐射损伤的修复而增强放疗对人NSCLC的疗效.厄洛替尼、贝伐珠单抗与胸部放疗联合试验正在 进行中.该三种药物联合治疗的新策略尚需制订.由于放疗可增强HSP90分子伴侣的功能从而引起肺癌细胞的 放疗抵抗,此通路的阻断剂可通过抑制HIF-1α和VEGF的表达进而抑制肺癌细胞的生存和血管生成,因而可能 用于减少放疗抵抗.在NSCLC和间皮瘤的临床前模型中,Aurora激酶抑制剂似乎对放疗具有增效作用. 相似文献
74.
Antonio Jimeno Cristina Grávalos Pilar Escudero Isabel Sevilla M. Eugenia Vega-Villegas Vicente Alonso Ignacio Juez Rocío García-Carbonero Humberto Bovio Ramón Colomer Hernán Cortés-Funes 《Clinical & translational oncology》2008,10(1):52-57
Objective The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities
in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal
growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC).
Methods and patients Patients with advanced CRC were treated with gefitinib administered daily for 21 days and capecitabine administered twice
daily for 14 days of a 21-day cycle. The dose levels of gefitinib (mg) and capecitabine (mg/m2 bid) assessed were 250/1000 and 250/ 1250. An expanded cohort was enrolled at the MTD to better characterise toxicity and
efficacy. A total of 32 previously treated patients were accrued. In the phase I part 10 subjects were treated, with one dose-limiting
toxicity. Overall 26 patients were treated at the MTD of the combination, which was gefitinib 250 mg/day and capecitabine
1250 mg/m2 twice daily.
Results The most frequent treatment-related adverse events included asthenia, diarrhoea, nausea, rash and anorexia. The incidence
profile was very similar in phases I and II. No objective responses were documented but 53% of the patients achieved stable
disease as best response to therapy.
Conclusions Capecitabine 1250 mg/m2 twice daily 14 of 21 days and gefitinib at 250 mg/day can be safely administered in combination. The combination is relatively
well tolerated. There were no objective responses, although an interesting stabilisation rate was documented, in previously
treated advanced CRC patients. 相似文献
75.
Martina Aida Angeles Federico Migliorelli Sergi Vidal-Sicart Adela Saco Jaume Ordi Cristina Ros Pere Fust Meritxell Munmany Sílvia Escura Núria Carreras Nuria Snchez-Izquierdo Jaume Pahisa Aureli Torn Pilar Paredes Marta del Pino 《Journal Of Gynecologic Oncology》2021,32(4)
ObjectiveWe aimed to evaluate the accuracy of sentinel lymph node (SLN) mapping with transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR) to detect lymph node (LN) metastases, in patients with intermediate and high-risk endometrial cancer (EC), focusing on its performance to detect paraaortic involvement.MethodsProspective study including women with preoperative intermediate or high-risk EC, according to ESMO-ESGO-ESTRO consensus, who underwent SLN mapping using the TUMIR approach. SLNs were preoperatively localized by planar and single photon emission computed tomography/computed tomography images, and intraoperatively by gamma-probe. Immediately after SLN excision, all women underwent systematic pelvic and paraaortic lymphadenectomy by laparoscopy.ResultsThe study included 102 patients. The intraoperative SLN detection rate was 79.4% (81/102). Pelvic and paraaortic drainage was observed in 92.6% (75/81) and 45.7% (37/81) women, respectively, being exclusively paraaortic in 7.4% (6/81). After systematic lymphadenectomy, LN metastases were identified in 19.6% (20/102) patients, with 45.0% (9/20) showing paraaortic involvement, which was exclusive in 15.0% (3/20). The overall sensitivity and negative predictive value (NPV) of SLNs by the TUMIR approach to detect lymphatic involvement were 87.5% and 97.0%, respectively; and 83.3% and 96.9%, for paraaortic metastases. After applying the MSKCC SLN mapping algorithm, the sensitivity and NPV were 93.8% and 98.5%, respectively.ConclusionThe TUMIR method provides valuable information of endometrial drainage in patients at higher risk of paraaortic LN involvement. The TUMIR approach showed a detection rate of paraaortic SLNs greater than 45% and a high sensitivity and NPV for paraaortic metastases in women with intermediate and high-risk EC. 相似文献
76.
77.
Nerea Becerra-Tomás Andrés Díaz-López Núria Rosique-Esteban Emilio Ros Pilar Buil-Cosiales Dolores Corella Ramon Estruch Montserrat Fitó Lluís Serra-Majem Fernando Arós Rosa Maria Lamuela-Raventós Miquel Fiol José Manuel Santos-Lozano Javier Díez-Espino Olga Portoles Jordi Salas-Salvadó 《Clinical nutrition (Edinburgh, Scotland)》2018,37(3):906-913
78.
Objective
In 2006, a large measles outbreak occurred in Catalonia (Spain), where the immunization schedule included two doses of MMR vaccine at 15 months and 4 years. The aim of this study was to investigate the vaccine effectiveness (VE) of MMR in children attending day-care and pre-school centres and to estimate the number of cases that would have been avoided by administering the first dose of MMR at 12 months.Methods
A retrospective cohort study was carried out between October 2006 and January 2007 in day-care and pre-school centres with confirmed measles cases. VE was calculated in children aged ≥15 months without previous measles infection. Cases avoided by advancing the first dose of MMR to 12 months were estimated by calculating the basic and effective reproduction number in centres where transmission outside the class was observed.Results
Fifteen centres and 1394 children were included. There were 77 confirmed cases (attack rate = 5.5%). Vaccination coverage of the 1121 children aged ≥15 months was 91.6% and VE was 96% (95%CI 89-98%).There were 33 (41%) cases in the 81 children aged 12-14 months. Advancing the first dose to 12 months would have prevented 74 cases (91.5%) and lowered the attack rate from 41% to 8.6%.Conclusions
Over 90% of cases in children aged 12-14 months would have been avoided by MMR administration at 12 rather than 15 months. We strongly recommend advancing the first dose of MMR to 12 months in order to reduce the risk of measles outbreaks. 相似文献79.
Raul Zamora-Ros Valerie Cayssials Mazda Jenab Joseph A. Rothwell Veronika Fedirko Krasimira Aleksandrova Anne Tjønneland Cecilie Kyrø Kim Overvad Marie-Christine Boutron-Ruault Franck Carbonnel Yahya Mahamat-Saleh Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Elissavet Valanou Effie Vasilopoulou Giovanna Masala Valeria Pala Salvatore Panico Rosario Tumino Fulvio Ricceri Elisabete Weiderpass Torkjel M. Sandanger Cristina Lasheras Antonio Agudo Maria-Jose Sánchez Pilar Amiano Carmen Navarro Eva Ardanaz Emily Sonestedt Bodil Ohlsson Lena Maria Nilsson Martin Rutegård Bas Bueno-de-Mesquita Kay-Thee Khaw Nicholas J. Wareham Kathryn Bradbury Heinz Freisling Isabelle Romieu Amanda J. Cross Paolo Vineis Augustin Scalbert 《European journal of epidemiology》2018,33(11):1063-1075
Polyphenols may play a chemopreventive role in colorectal cancer (CRC); however, epidemiological evidence supporting a role for intake of individual polyphenol classes, other than flavonoids is insufficient. We evaluated the association between dietary intakes of total and individual classes and subclasses of polyphenols and CRC risk and its main subsites, colon and rectum, within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. The cohort included 476,160 men and women from 10 European countries. During a mean follow-up of 14 years, there were 5991 incident CRC cases, of which 3897 were in the colon and 2094 were in the rectum. Polyphenol intake was estimated using validated centre/country specific dietary questionnaires and the Phenol-Explorer database. In multivariable-adjusted Cox regression models, a doubling in total dietary polyphenol intake was not associated with CRC risk in women (HRlog2?=?1.06, 95% CI 0.99–1.14) or in men (HRlog2?=?0.97, 95% CI 0.90–1.05), respectively. Phenolic acid intake, highly correlated with coffee consumption, was inversely associated with colon cancer in men (HRlog2?=?0.91, 95% CI 0.85–0.97) and positively associated with rectal cancer in women (HRlog2?=?1.10, 95% CI 1.02–1.19); although associations did not exceed the Bonferroni threshold for significance. Intake of other polyphenol classes was not related to colorectal, colon or rectal cancer risks. Our study suggests a possible inverse association between phenolic acid intake and colon cancer risk in men and positive with rectal cancer risk in women. 相似文献
80.
Sara Ares-Blanco María Pilar Astier-Peña Raquel Gómez-Bravo María Fernández-García José Miguel Bueno-Ortiz 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2021,53(10):102132
This article describes the management of human resource and the vaccination strategies in primary care in twelve European countries in relation to the COVID-19 pandemic. All the countries have found solutions to increase their workforce in primary care. Other healthcare professionals were incorporated to support family doctors assuming their tasks, under their supervision and coordination. The European Commission had a crucial role in the production, purchase and distribution of the vaccines. The engagement of primary care in the vaccination campaign has had an unequal participation in the different countries, although the greatest burden has been managed from the government's public health departments. 相似文献